Logo image of SNTI

SENTI BIOSCIENCES INC (SNTI) Stock Fundamental Analysis

USA - NASDAQ:SNTI - US81726A2096 - Common Stock

1.39 USD
+0.02 (+1.46%)
Last: 9/18/2025, 8:24:55 PM
1.3606 USD
-0.03 (-2.12%)
After Hours: 9/18/2025, 8:24:55 PM
Fundamental Rating

3

Overall SNTI gets a fundamental rating of 3 out of 10. We evaluated SNTI against 540 industry peers in the Biotechnology industry. The financial health of SNTI is average, but there are quite some concerns on its profitability. SNTI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SNTI had negative earnings in the past year.
SNTI had a negative operating cash flow in the past year.
In the past 5 years SNTI always reported negative net income.
In the past 5 years SNTI always reported negative operating cash flow.
SNTI Yearly Net Income VS EBIT VS OCF VS FCFSNTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

SNTI's Return On Assets of -53.95% is in line compared to the rest of the industry. SNTI outperforms 47.41% of its industry peers.
SNTI has a Return On Equity (-104.01%) which is in line with its industry peers.
Industry RankSector Rank
ROA -53.95%
ROE -104.01%
ROIC N/A
ROA(3y)-48.54%
ROA(5y)-48.79%
ROE(3y)-85.31%
ROE(5y)-82.36%
ROIC(3y)N/A
ROIC(5y)N/A
SNTI Yearly ROA, ROE, ROICSNTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

SNTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNTI Yearly Profit, Operating, Gross MarginsSNTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

6

2. Health

2.1 Basic Checks

SNTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNTI has more shares outstanding
SNTI has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, SNTI has a worse debt to assets ratio.
SNTI Yearly Shares OutstandingSNTI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SNTI Yearly Total Debt VS Total AssetsSNTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -5.27, we must say that SNTI is in the distress zone and has some risk of bankruptcy.
SNTI's Altman-Z score of -5.27 is on the low side compared to the rest of the industry. SNTI is outperformed by 61.48% of its industry peers.
There is no outstanding debt for SNTI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.27
ROIC/WACCN/A
WACC9.56%
SNTI Yearly LT Debt VS Equity VS FCFSNTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 4.49 indicates that SNTI has no problem at all paying its short term obligations.
SNTI has a Current ratio (4.49) which is comparable to the rest of the industry.
A Quick Ratio of 4.49 indicates that SNTI has no problem at all paying its short term obligations.
SNTI has a Quick ratio (4.49) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.49
Quick Ratio 4.49
SNTI Yearly Current Assets VS Current LiabilitesSNTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

SNTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -115.47%.
The Revenue for SNTI has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-115.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.87%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SNTI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.35% yearly.
SNTI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 82.38% yearly.
EPS Next Y83.63%
EPS Next 2Y37.84%
EPS Next 3Y22.36%
EPS Next 5Y12.35%
Revenue Next Year-64.29%
Revenue Next 2Y-5.51%
Revenue Next 3Y-25.99%
Revenue Next 5Y82.38%

3.3 Evolution

SNTI Yearly Revenue VS EstimatesSNTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2029 2030 2031 100M 200M 300M
SNTI Yearly EPS VS EstimatesSNTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SNTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNTI Price Earnings VS Forward Price EarningsSNTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNTI Per share dataSNTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

SNTI's earnings are expected to grow with 22.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.84%
EPS Next 3Y22.36%

More info and screens

0

5. Dividend

5.1 Amount

SNTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENTI BIOSCIENCES INC

NASDAQ:SNTI (9/18/2025, 8:24:55 PM)

After market: 1.3606 -0.03 (-2.12%)

1.39

+0.02 (+1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-13 2025-11-13
Inst Owners28.21%
Inst Owner Change13.58%
Ins Owners0.85%
Ins Owner Change0%
Market Cap36.36M
Analysts82.5
Price Target13.77 (890.65%)
Short Float %2.14%
Short Ratio0.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)35.68%
EPS NY rev (3m)-26.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-80%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-11.54
EYN/A
EPS(NY)-2.43
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS0
BVpS1.94
TBVpS1.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.95%
ROE -104.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.54%
ROA(5y)-48.79%
ROE(3y)-85.31%
ROE(5y)-82.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.49
Quick Ratio 4.49
Altman-Z -5.27
F-Score3
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)1059.06%
Cap/Depr(5y)820.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-115.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.87%
EPS Next Y83.63%
EPS Next 2Y37.84%
EPS Next 3Y22.36%
EPS Next 5Y12.35%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-64.29%
Revenue Next 2Y-5.51%
Revenue Next 3Y-25.99%
Revenue Next 5Y82.38%
EBIT growth 1Y20.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.99%
OCF growth 3YN/A
OCF growth 5YN/A